A recent report found that tofacitinib did not directly affect RA synovial monocytes, but that tofacitinib-exposed CD4+ T cells demonstrated reduced proliferation, impaired IL-17 and IFNγ expression, and generated conditioned medium that when added to CD14+ monocytes could inhibit IL-8 production (229). The gene discussed is CD4; the disease is rheumatoid arthritis.